Newborn screening disorders increasingly require genetic variant analysis as part of second-tier or confirmatory testing. Sanger sequencing and gene-specific next-generation sequencing (NGS)-based tests, the current methods of choice, are costly and lack scalability when expanding to new conditions. We describe a scalable, exome sequencing–based NGS pipeline with a priori analysis restriction that can be universally applied to any NBS disorder.
De-identified abnormal newborn screening specimens representing severe combined immune deficiency (SCID), cystic fibrosis (CF), VLCAD deficiency, metachromatic leukodystrophy (MLD), and in silico sequence read data sets were used to validate the pipeline. To support interpretation and clinical decision-making within the bioinformatics pipeline, variants from multiple databases were curated and validated.
CFTR variant panel analysis correctly identified all variants. Concordance compared with diagnostic testing results for targeted gene analysis was between 78.6% and 100%. Validation of the bioinformatics pipeline with in silico data sets revealed a 100% detection rate. Varying degrees of overlap were observed between ClinVar and other databases ranging from 3% to 65%. Data normalization revealed that 11% of variants across the databases required manual curation.
This pipeline allows for restriction of analysis to variants within a single gene or multiple genes, and can be readily expanded to full exome analysis if clinically indicated and parental consent is granted.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Sequence analysis pipelines and read simulation data sets are available at https://github.com/UtahNBS/WES-Secondary-Testing.
Code developed for the variant database curation pipeline is available at https://github.com/eilbecklab/Utah-DOH-newborn-screening.
Bodian, D. L. et al. Utility of whole-genome sequencing for detection of newborn screening disorders in a population cohort of 1,696 neonates. Genet. Med. 18, 221–230 (2016).
Johnston, J. et al. Sequencing newborns: a call for nuanced use of genomic technologies. Hastings Cent. Rep. 48(Suppl 2), S2–S6 (2018).
Landau, Y. E., Lichter-Konecki, U. & Levy, H. L. Genomics in newborn screening. J. Pediatr. 164, 14–19 (2014).
Bodamer, O. A., Scott, C. R. & Giugliani, R., Pompe Disease Newborn Screening Working Group. Newborn screening for Pompe disease. Pediatrics. 140(Suppl 1), S4–S13 (2017).
Burton, B. K., Kronn, D. F., Hwu, W. L. & Kishnani, P. S. The initial evaluation of patients after positive newborn screening: recommended algorithms leading to a confirmed diagnosis of Pompe disease. Pediatrics. 140(Suppl 1), S14–S23 (2017).
Arnold, W. D., Kassar, D. & Kissel, J. T. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 51, 157–167 (2015).
Clarke, L. A. et al. Mucopolysaccharidosis type I newborn screening: best practices for diagnosis and management. J. Pediatr. 182, 363–370 (2017).
Kemper, A. R. et al. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. Genet. Med. 19, 121–126 (2017).
Schram, C. A. Atypical cystic fibrosis: identification in the primary care setting. Can. Fam. Physician 58, 1341–1345 (2012).
Harrington, M. et al. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J. Rare Dis. 14, 89 (2019).
Oksenhendler, E. et al. Infections in 252 patients with common variable immunodeficiency. Clin. Infect. Dis. 46, 1547–1554 (2008).
Shchelochkov, O., Wong, L. J., Shaibani, A. & Shinawi, M. Atypical presentation of VLCAD deficiency associated with a novel ACADVL splicing mutation. Muscle Nerve 39, 374–382 (2009).
Baker, M. W. et al. Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study. Genet. Med. 18, 231–238 (2016).
Kharrazi, M. et al. Newborn screening for cystic fibrosis in California. Pediatrics. 136, 1062–1072 (2015).
Taylor, J. L. et al. The North Carolina experience with mucopolysaccharidosis type I newborn screening. J. Pediatr. 211, e192 (2019).
Lee, S. et al. Evaluation of X-linked adrenoleukodystrophy newborn screening in North Carolina. JAMA Netw. Open 3, e1920356 (2020).
van Nimwegen, K. J. et al. Is the $1000 genome as near as we think? A cost analysis of next-generation sequencing. Clin. Chem 62, 1458–1464 (2016).
Amberger, J. S., Bocchini, C. A., Scott, A. F. & Hamosh, A. OMIM.org: leveraging knowledge across phenotype-gene relationships. Nucleic Acids Res. 47, D1038–D1043 (2019).
Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 581, 434–443 (2020).
Wang, M. et al. hgvs: a Python package for manipulating sequence variants using HGVS nomenclature: 2018 update. Hum. Mutat. 39, 1803–1813 (2018).
Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.11–33 (2013).
Köster, J. & Rahmann, S. Snakemake—a scalable bioinformatics workflow engine. Bioinformatics. 28, 2520–2522 (2012).
Stephens, Z. D. et al. Simulating next-generation sequencing data sets from empirical mutation and sequencing models. PLoS One 11, e0167047 (2016).
Hong, X. et al. Toward newborn screening of metachromatic leukodystrophy: results from analysis of over 27,000 newborn dried blood spots. Genet Med. https://doi.org/10.1038/s41436-020-01017-5 (2020).
Hirschhorn, R. Identification of two new missense mutations (R156C and S291L) in two ADA- SCID patients unusual for response to therapy with partial exchange transfusions. Hum. Mutat. 1, 166–168 (1992).
Cox, D. M. & Butler, M. G. The 15q11.2 BP1–BP2 microdeletion syndrome: a review. Int. J. Mol. Sci. 16, 4068–4082 (2015).
Deignan, J. L. et al. CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. https://doi.org/10.1038/s41436-020-0822-5 (2020).
Thauvin-Robinet, C. et al. CFTR p.Arg117His associated with CBAVD and other CFTR-related disorders. J. Med. Genet. 50, 220–227 (2013).
Bienvenu, T., Beldjord, C., Adjiman, M. & Kaplan, J. C. Male infertility as the only presenting sign of cystic fibrosis when homozygous for the mild mutation R117H. J. Med. Genet. 30, 797 (1993).
Fokkema, I. F. et al. LOVD v.2.0: the next generation in gene variant databases. Hum. Mutat. 32, 557–563 (2011).
den Dunnen, J. T. et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum. Mutat. 37, 564–569 (2016).
Stevens, C. Next Generation Sequencing in the New York State Newborn Screening Molecular Lab. https://www.aphl.org/programs/newborn_screening/Documents/2017%20Gene%20Sequencing%20Meeting/Stevens_Second%20Tier%20and%20Future%20Applications.pdf. Accessed 7 Aug 2020.
van Rappard, D. F., Boelens, J. J. & Wolf, N. I. Metachromatic leukodystrophy: disease spectrum and approaches for treatment. Best. Pract. Res. Clin. Endocrinol. Metab. 29, 261–273 (2015).
Rice, G. M. & Steiner, R. D. Inborn errors of metabolism (metabolic disorders). Pediatr. Rev. 37, 3–15 (2016).
Rehm, H. L. et al. ClinGen—the Clinical Genome Resource. N. Engl. J. Med. 372, 2235–2242 (2015).
Zastrow, D. B. et al. Unique aspects of sequence variant interpretation for inborn errors of metabolism (IEM): the ClinGen IEM Working Group and the phenylalanine hydroxylase gene. Hum. Mutat. 39, 1569–1580 (2018).
Aziz, N. et al. College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests. Arch. Pathol. Lab. Med. 139, 481–493 (2015).
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–423 (2015).
Luh, F. & Yen, Y. FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine. NPJ Genom. Med. 3, 28 (2018).
Roy, S. et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists. J. Mol. Diagn. 20, 4–27 (2018).
Drendel, H. M. et al. Intermediate MCAD deficiency associated with a novel mutation of the ACADM gene: c.1052C>T. Case Rep. Genet. 2015, 532090 (2015).
Rivera-Muñoz, E. A. et al. ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation. Hum. Mutat. 39, 1614–1622 (2018).
This work was supported by the Association of Public Health Laboratories through the Health Resources and Services Administration (HRSA), US Department of Health and Human Services (HHS UG9MC30369). This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, or the US Government. Funding was also provided by the National Institutes of Health, National Human Genome Research Institute (5U41HG009650 to K.E.) and National Library of Medicine (T15LM007124 to D.S.).
Institutional review board (IRB) approval for the analysis of MLD screen-positive and screen-negative samples was granted by the Washington state IRB Project B-062702-H07.23. The Utah Department of Health IRB determined that IRB approval was not required for work utilizing de-identified CF, SCID, and VLCAD deficiency specimens, as these were analyzed as a part of a validation and process improvement project.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ruiz-Schultz, N., Sant, D., Norcross, S. et al. Methods and feasibility study for exome sequencing as a universal second-tier test in newborn screening. Genet Med (2021). https://doi.org/10.1038/s41436-020-01058-w